BTIG Research Issues Pessimistic Forecast for Evolent Health (NYSE:EVH) Stock Price

by · The Cerbat Gem

Evolent Health (NYSE:EVH – Get Free Report) had its target price decreased by stock analysts at BTIG Research from $20.00 to $16.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the technology company’s stock. BTIG Research’s target price would suggest a potential upside of 222.26% from the company’s current price.

EVH has been the topic of a number of other research reports. Zacks Research cut shares of Evolent Health from a “hold” rating to a “strong sell” rating in a report on Friday, October 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Evolent Health in a research note on Wednesday, October 8th. Truist Financial boosted their price objective on Evolent Health from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Stephens reissued an “equal weight” rating and issued a $9.00 price objective on shares of Evolent Health in a report on Wednesday, September 24th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 target price on shares of Evolent Health in a research note on Tuesday, September 9th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $15.54.

Check Out Our Latest Stock Analysis on EVH

Evolent Health Stock Performance

Shares of NYSE:EVH traded down $1.04 during trading on Friday, hitting $4.97. 8,672,165 shares of the company traded hands, compared to its average volume of 2,714,703. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.72. The business’s fifty day moving average is $8.26 and its 200-day moving average is $9.07. The stock has a market capitalization of $583.43 million, a price-to-earnings ratio of -3.08 and a beta of 0.58. Evolent Health has a one year low of $4.92 and a one year high of $15.56.

Evolent Health (NYSE:EVH – Get Free Report) last released its quarterly earnings data on Tuesday, June 4th. The technology company reported $0.21 earnings per share (EPS) for the quarter. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The business had revenue of $427.70 million during the quarter. As a group, equities analysts predict that Evolent Health will post 0.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Evolent Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. Banque Cantonale Vaudoise bought a new stake in shares of Evolent Health during the 1st quarter worth $25,000. Nisa Investment Advisors LLC raised its position in shares of Evolent Health by 88.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock worth $29,000 after purchasing an additional 1,194 shares during the period. Parallel Advisors LLC lifted its holdings in shares of Evolent Health by 82.6% during the second quarter. Parallel Advisors LLC now owns 3,487 shares of the technology company’s stock valued at $39,000 after purchasing an additional 1,577 shares during the last quarter. Strs Ohio acquired a new position in shares of Evolent Health in the 1st quarter valued at $47,000. Finally, US Bancorp DE increased its stake in Evolent Health by 291.0% in the 1st quarter. US Bancorp DE now owns 5,153 shares of the technology company’s stock worth $49,000 after purchasing an additional 3,835 shares in the last quarter.

Evolent Health Company Profile

(Get Free Report)

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

Featured Articles